These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
250 related articles for article (PubMed ID: 8557344)
1. Further characterization of delta aroA delta virG Shigella flexneri 2a strain CVD 1203 as a mucosal Shigella vaccine and as a live-vector vaccine for delivering antigens of enterotoxigenic Escherichia coli. Noriega FR; Losonsky G; Wang JY; Formal SB; Levine MM Infect Immun; 1996 Jan; 64(1):23-7. PubMed ID: 8557344 [TBL] [Abstract][Full Text] [Related]
2. Attenuated Shigella flexneri 2a Delta guaBA strain CVD 1204 expressing enterotoxigenic Escherichia coli (ETEC) CS2 and CS3 fimbriae as a live mucosal vaccine against Shigella and ETEC infection. Altboum Z; Barry EM; Losonsky G; Galen JE; Levine MM Infect Immun; 2001 May; 69(5):3150-8. PubMed ID: 11292735 [TBL] [Abstract][Full Text] [Related]
3. Attenuated Shigella flexneri 2a vaccine strain CVD 1204 expressing colonization factor antigen I and mutant heat-labile enterotoxin of enterotoxigenic Escherichia coli. Koprowski H; Levine MM; Anderson RJ; Losonsky G; Pizza M; Barry EM Infect Immun; 2000 Sep; 68(9):4884-92. PubMed ID: 10948101 [TBL] [Abstract][Full Text] [Related]
4. Immunogenicity of multivalent Shigella-ETEC candidate vaccine strains in a guinea pig model. Barry EM; Wang J; Wu T; Davis T; Levine MM Vaccine; 2006 May; 24(18):3727-34. PubMed ID: 16169130 [TBL] [Abstract][Full Text] [Related]
5. Safety, immunogenicity, and transmissibility in humans of CVD 1203, a live oral Shigella flexneri 2a vaccine candidate attenuated by deletions in aroA and virG. Kotloff KL; Noriega F; Losonsky GA; Sztein MB; Wasserman SS; Nataro JP; Levine MM Infect Immun; 1996 Nov; 64(11):4542-8. PubMed ID: 8890204 [TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and characterization of WRSF2G11: a second generation live attenuated Shigella flexneri 2a vaccine strain. Ranallo RT; Thakkar S; Chen Q; Venkatesan MM Vaccine; 2007 Mar; 25(12):2269-78. PubMed ID: 17229494 [TBL] [Abstract][Full Text] [Related]
7. Engineered deltaguaB-A deltavirG Shigella flexneri 2a strain CVD 1205: construction, safety, immunogenicity, and potential efficacy as a mucosal vaccine. Noriega FR; Losonsky G; Lauderbaugh C; Liao FM; Wang JY; Levine MM Infect Immun; 1996 Aug; 64(8):3055-61. PubMed ID: 8757833 [TBL] [Abstract][Full Text] [Related]
8. Construction and characterization of attenuated delta aroA delta virG Shigella flexneri 2a strain CVD 1203, a prototype live oral vaccine. Noriega FR; Wang JY; Losonsky G; Maneval DR; Hone DM; Levine MM Infect Immun; 1994 Nov; 62(11):5168-72. PubMed ID: 7927802 [TBL] [Abstract][Full Text] [Related]
9. Construction and characterization of virG (icsA)-deleted Escherichia coli K12-Shigella flexneri hybrid vaccine strains. Alexander WA; Hartman AB; Oaks EV; Venkatesan MM Vaccine; 1996 Aug; 14(11):1053-61. PubMed ID: 8879102 [TBL] [Abstract][Full Text] [Related]
10. Regulated Delayed Su H; Liu Q; Wang S; Curtiss R; Kong Q Theranostics; 2019; 9(12):3565-3579. PubMed ID: 31281498 [No Abstract] [Full Text] [Related]
11. Construction of a novel Shigella live-vector strain co-expressing CS3 and LTB/STm of enterotoxigenic E.coli. Zheng JP; Zhang ZS; Li SQ; Liu XX; Yuan SL; Wang P; Zhan DW; Wang LC; Huang CF World J Gastroenterol; 2005 Jun; 11(22):3411-8. PubMed ID: 15948247 [TBL] [Abstract][Full Text] [Related]
12. Local immune response and protection in the guinea pig keratoconjunctivitis model following immunization with Shigella vaccines. Hartman AB; Van de Verg LL; Collins HH; Tang DB; Bendiuk NO; Taylor DN; Powell CJ Infect Immun; 1994 Feb; 62(2):412-20. PubMed ID: 7507892 [TBL] [Abstract][Full Text] [Related]